{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:50:57Z","timestamp":1789732257485,"version":"4.0.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41591-024-03195-0","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T06:02:19Z","timestamp":1723701739000},"page":"2499-2507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-0139","authenticated-orcid":false,"given":"Justin","family":"Jee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-0149","authenticated-orcid":false,"given":"A. Rose","family":"Brannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1326-7249","authenticated-orcid":false,"given":"Rohan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Pichotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-9985","authenticated-orcid":false,"given":"Monica","family":"Diosdado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-5387","authenticated-orcid":false,"given":"Clare","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-6554","authenticated-orcid":false,"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-1222","authenticated-orcid":false,"given":"Stephen","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6402-523X","authenticated-orcid":false,"given":"Sohrab P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-0576","authenticated-orcid":false,"given":"Pedram","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-7213","authenticated-orcid":false,"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-4904","authenticated-orcid":false,"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5000","authenticated-orcid":false,"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6661-8733","authenticated-orcid":false,"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-5261","authenticated-orcid":false,"given":"Simon","family":"Mantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"3195_CR1","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","volume":"18","author":"GH Lyman","year":"2013","unstructured":"Lyman, G. H., Eckert, L., Wang, Y., Wang, H. & Cohen, A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 18, 1321\u20131329 (2013).","journal-title":"Oncologist"},{"key":"3195_CR2","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","volume":"164","author":"GH Lyman","year":"2018","unstructured":"Lyman, G. H., Culakova, E., Poniewierski, M. S. & Kuderer, N. M. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb. Res. 164, S112\u2013S118 (2018).","journal-title":"Thromb. Res."},{"key":"3195_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M. & Lyman, G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5, 632\u2013634 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"3195_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli, G. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 366, 601\u2013609 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3195_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","volume":"10","author":"G Agnelli","year":"2009","unstructured":"Agnelli, G. et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10, 943\u2013949 (2009).","journal-title":"Lancet Oncol."},{"key":"3195_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2018","unstructured":"Carrier, M. et al. Apixaban to prevent venous thromboembolism in patients with cancer. N. Engl. J. Med. 380, 711\u2013719 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3195_CR7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana, A. A. et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N. Engl. J. Med. 380, 720\u2013728 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3195_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/cncr.32724","volume":"126","author":"A Li","year":"2020","unstructured":"Li, A. et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer 126, 1736\u20131748 (2020).","journal-title":"Cancer"},{"key":"3195_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman, G. H. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 5, 927\u2013974 (2021).","journal-title":"Blood Adv."},{"key":"3195_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2019","unstructured":"Key, N. S. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 38, 496\u2013520 (2019).","journal-title":"J. Clin. Oncol."},{"key":"3195_CR11","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H. & Francis, C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111, 4902\u20134907 (2008).","journal-title":"Blood"},{"key":"3195_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1634\/theoncologist.2017-0205","volume":"23","author":"NM Kuderer","year":"2018","unstructured":"Kuderer, N. M. et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncologist 23, 247\u2013255 (2018).","journal-title":"Oncologist"},{"key":"3195_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jth.13378","volume":"14","author":"AS Mansfield","year":"2016","unstructured":"Mansfield, A. S. et al. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J. Thromb. Haemost. 14, 1773\u20131778 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"3195_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","volume":"104","author":"FI Mulder","year":"2019","unstructured":"Mulder, F. I. et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 104, 1277 (2019).","journal-title":"Haematologica"},{"key":"3195_CR15","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.22.01542","volume":"41","author":"A Li","year":"2023","unstructured":"Li, A. et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems. J. Clin. Oncol. 41, 2926\u20132938 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3195_CR16","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","volume":"5","author":"I Pabinger","year":"2018","unstructured":"Pabinger, I. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 5, e289\u2013e298 (2018).","journal-title":"Lancet Haematol."},{"key":"3195_CR17","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.23.00100","volume":"41","author":"JM Connors","year":"2023","unstructured":"Connors, J. M. Fine tuning venous thromboembolism risk prediction in patients with cancer. J. Clin. Oncol. 41, 2881\u20132883 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3195_CR18","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1200\/JOP.19.00697","volume":"16","author":"CE Holmes","year":"2020","unstructured":"Holmes, C. E. et al. Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic. JCO Oncol. Pract. 16, e868\u2013e874 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"3195_CR19","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1016\/S2352-3026(18)30067-X","volume":"5","author":"AA Khorana","year":"2018","unstructured":"Khorana, A. A. Simplicity versus complexity: an existential dilemma as risk tools evolve. Lancet Haematol. 5, e273\u2013e274 (2018).","journal-title":"Lancet Haematol."},{"key":"3195_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom, J. W., Doggen, C. J. M., Osanto, S. & Rosendaal, F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715\u2013722 (2005).","journal-title":"JAMA"},{"key":"3195_CR21","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.22.00255","volume":"41","author":"A Mu\u00f1oz","year":"2023","unstructured":"Mu\u00f1oz, A. et al. A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts. J. Clin. Oncol. 41, 2911\u20132925 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3195_CR22","doi-asserted-by":"publisher","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","volume":"15","author":"JI Zwicker","year":"2009","unstructured":"Zwicker, J. I. et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 15, 6830\u20136840 (2009).","journal-title":"Clin. Cancer Res."},{"key":"3195_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1182\/blood.V122.21.1127.1127","volume":"122","author":"AA Khorana","year":"2013","unstructured":"Khorana, A. A. et al. A proteomics-based approach to identifying mechanisms of cancer-associated thrombosis: potential role for immunoglobulins. Blood 122, 1127 (2013).","journal-title":"Blood"},{"key":"3195_CR24","unstructured":"FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers. US FDA www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers (2020)."},{"key":"3195_CR25","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","volume":"107","author":"TA Fuchs","year":"2010","unstructured":"Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl Acad. Sci. USA 107, 15880\u201315885 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3195_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jth.13951","volume":"16","author":"L-M Mauracher","year":"2018","unstructured":"Mauracher, L.-M. et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J. Thromb. Haemost. 16, 508\u2013518 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"3195_CR27","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. 28, 2353\u20132363 (2022).","journal-title":"Nat. Med."},{"key":"3195_CR28","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/s41591-022-02068-8","volume":"28","author":"A Vivancos","year":"2022","unstructured":"Vivancos, A. & Tabernero, J. Circulating tumor DNA as a novel prognostic indicator. Nat. Med. 28, 2255\u20132256 (2022).","journal-title":"Nat. Med."},{"key":"3195_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616, 553\u2013562 (2023).","journal-title":"Nature"},{"key":"3195_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","volume":"22","author":"MM Syeda","year":"2021","unstructured":"Syeda, M. M. et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 22, 370\u2013380 (2021).","journal-title":"Lancet Oncol."},{"key":"3195_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Reichert, Z. R. et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. 34, 111\u2013120 (2023).","journal-title":"Ann. Oncol."},{"key":"3195_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24109-5","volume":"12","author":"A Rose Brannon","year":"2021","unstructured":"Rose Brannon, A. et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat. Commun. 12, 3770 (2021).","journal-title":"Nat. Commun."},{"key":"3195_CR33","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp, J. F., Braekkan, S. K., Versteeg, H. H. & Cannegieter, S. C. Epidemiology of cancer-associated venous thrombosis. Blood 122, 1712\u20131723 (2013).","journal-title":"Blood"},{"key":"3195_CR34","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.2020007488","volume":"137","author":"A Dunbar","year":"2021","unstructured":"Dunbar, A. et al. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood 137, 2103\u20132113 (2021).","journal-title":"Blood"},{"key":"3195_CR35","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014)."},{"key":"3195_CR36","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/cncr.21496","volume":"104","author":"AA Khorana","year":"2005","unstructured":"Khorana, A. A., Francis, C. W., Culakova, E. & Lyman, G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104, 2822\u20132829 (2005).","journal-title":"Cancer"},{"key":"3195_CR37","doi-asserted-by":"publisher","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun, S. et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS ONE 10, e0140830 (2015).","journal-title":"PLoS ONE"},{"key":"3195_CR38","doi-asserted-by":"crossref","unstructured":"Morbelli, S. et al. Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): 18F-FDG PET\/CT study. J. Nucl. Med. 58, 1764\u20131769 (2017).","DOI":"10.2967\/jnumed.117.193201"},{"key":"3195_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245\u2013251 (2020).","journal-title":"Nature"},{"key":"3195_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11147-z","volume":"23","author":"AL Ottestad","year":"2023","unstructured":"Ottestad, A. L. et al. Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18F-FDG PET\/CT in early-stage non-small cell lung cancer. BMC Cancer 23, 646 (2023).","journal-title":"BMC Cancer"},{"key":"3195_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ YOUDEN","year":"1950","unstructured":"YOUDEN, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"3195_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1466-8238.2007.00358.x","volume":"17","author":"JM Lobo","year":"2008","unstructured":"Lobo, J. M., Jim\u00e9nez-Valverde, A. & Real, R. AUC: a misleading measure of the performance of predictive distribution models. Glob. Ecol. Biogeogr. 17, 145\u2013151 (2008).","journal-title":"Glob. Ecol. Biogeogr."},{"key":"3195_CR43","first-page":"383","volume":"121","author":"A Cohen","year":"2020","unstructured":"Cohen, A. et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb. Haemost. 121, 383\u2013395 (2020).","journal-title":"Thromb. Haemost."},{"key":"3195_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.amjmed.2009.05.025","volume":"123","author":"D Khemasuwan","year":"2010","unstructured":"Khemasuwan, D., Divietro, M. L., Tangdhanakanond, K., Pomerantz, S. C. & Eiger, G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am. J. Med. 123, 60\u201365 (2010).","journal-title":"Am. J. Med."},{"key":"3195_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.thromres.2017.08.001","volume":"158","author":"SM El-Refai","year":"2017","unstructured":"El-Refai, S. M., Black, E. P., Adams, V. R., Talbert, J. C. & Brown, J. D. Statin use and venous thromboembolism in cancer: a large, active comparator, propensity score matched cohort study. Thromb. Res. 158, 49\u201358 (2017).","journal-title":"Thromb. Res."},{"key":"3195_CR46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1074248420925021","volume":"25","author":"P Li","year":"2020","unstructured":"Li, P. et al. Aspirin is associated with reduced rates of venous thromboembolism in older patients with cancer. J. Cardiovasc. Pharmacol. Ther. 25, 456\u2013465 (2020).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"3195_CR47","unstructured":"Trousseau, A. Phlegmasia alba dolens. In Clinique medicale l\u2019H\u00f4tel-Dieu Paris 2nd edn, Vol. 3. 654\u2013712 (J.-B. Bailli\u00e8re et fils, 1865)."},{"key":"3195_CR48","first-page":"241","volume":"142","author":"P Mandel","year":"1948","unstructured":"Mandel, P. & Metais, P. [Nuclear acids in human blood plasma]. C. R. Seances Soc. Biol. Fil. 142, 241\u2013243 (1948).","journal-title":"C. R. Seances Soc. Biol. Fil."},{"key":"3195_CR49","doi-asserted-by":"publisher","first-page":"13076","DOI":"10.1073\/pnas.1200419109","volume":"109","author":"M Demers","year":"2012","unstructured":"Demers, M. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl Acad. Sci. USA 109, 13076\u201313081 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3195_CR50","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/j.1538-7836.2011.04465.x","volume":"9","author":"LL Swystun","year":"2011","unstructured":"Swystun, L. L., Mukherjee, S. & Liaw, P. C. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J. Thromb. Haemost. 9, 2313\u20132321 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"3195_CR51","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858\u2013873 (2021).","journal-title":"Cancer Discov."},{"key":"3195_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic\u2014implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297\u2013312 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3195_CR53","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/ijc.33834","volume":"150","author":"V Conteduca","year":"2022","unstructured":"Conteduca, V. et al. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int. J. Cancer 150, 1166\u20131173 (2022).","journal-title":"Int. J. Cancer"},{"key":"3195_CR54","doi-asserted-by":"publisher","unstructured":"Mantha, S. et al. Application of machine learning to the prediction of cancer-associated venous thromboembolism. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-2870367\/v1 (2023).","DOI":"10.21203\/rs.3.rs-2870367\/v1"},{"key":"3195_CR55","doi-asserted-by":"publisher","first-page":"8781379","DOI":"10.1155\/2017\/8781379","volume":"2017","author":"P Ferroni","year":"2017","unstructured":"Ferroni, P. et al. Validation of a machine learning approach for venous thromboembolism risk prediction in oncology. Dis. Markers 2017, 8781379 (2017).","journal-title":"Dis. Markers"},{"key":"3195_CR56","doi-asserted-by":"crossref","unstructured":"Mattox, A. K. et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov. 13, 2166\u20132179 (2023).","DOI":"10.1158\/2159-8290.CD-21-1252"},{"key":"3195_CR57","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1182\/blood-2023-184751","volume":"142","author":"L Gervaso","year":"2023","unstructured":"Gervaso, L. et al. Circulating tumor DNA and risk of venous thromboembolism in locally advanced rectal cancer. Blood 142, 4013 (2023).","journal-title":"Blood"},{"key":"3195_CR58","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842\u20131853 (2020).","journal-title":"Cancer Discov."},{"key":"3195_CR59","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223\u2013238 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"3195_CR60","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"3195_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/ATVBAHA.122.318463","volume":"43","author":"T Gi","year":"2023","unstructured":"Gi, T. et al. Histopathological features of cancer-associated venous thromboembolism: presence of intrathrombus cancer cells and prothrombotic factors. Arterioscler. Thromb. Vasc. Biol. 43, 146\u2013159 (2023).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"3195_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57\u201368 (2016).","journal-title":"Cell"},{"key":"3195_CR63","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3324\/haematol.2016.142471","volume":"102","author":"S Pfeiler","year":"2017","unstructured":"Pfeiler, S., Stark, K., Massberg, S. & Engelmann, B. Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica 102, 206\u2013213 (2017).","journal-title":"Haematologica"},{"key":"3195_CR64","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo, C. et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 16, 1647\u20131662 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"3195_CR65","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJM199210153271604","volume":"327","author":"P Prandoni","year":"1992","unstructured":"Prandoni, P. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 327, 1128\u20131133 (1992).","journal-title":"N. Engl. J. Med."},{"key":"3195_CR66","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.tru.2020.100030","volume":"2","author":"N Kraaijpoel","year":"2021","unstructured":"Kraaijpoel, N. et al. Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: rationale and design of the PLATO-VTE study. Thromb. Update 2, 100030 (2021).","journal-title":"Thromb. Update"},{"key":"3195_CR67","unstructured":"Kaiser, J. \u2018The complexities are staggering.\u2019 U.S. plans huge trial of blood tests for multiple cancers. Science https:\/\/www.science.org\/content\/article\/complexities-are-staggering-u-s-plans-huge-trial-blood-tests-multiple-cancers (2022)."},{"key":"3195_CR68","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/d41573-023-00111-y","volume":"22","author":"W Xie","year":"2023","unstructured":"Xie, W., Suryaprakash, S., Wu, C., Rodriguez, A. & Fraterman, S. Trends in the uses of liquid biopsy in oncology. Nat. Rev. Drug Discov. 22, 612\u2013613 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3195_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme, P. et al. Abelacimab for prevention of venous thromboembolism. N. Engl. J. Med. 385, 609\u2013617 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3195_CR70","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA 329, 1924\u20131933 (2023).","journal-title":"JAMA"},{"key":"3195_CR71","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","volume":"22","author":"CP Paweletz","year":"2016","unstructured":"Paweletz, C. P. et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin. Cancer Res. 22, 915\u2013922 (2016).","journal-title":"Clin. Cancer Res."},{"key":"3195_CR72","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 1141\u20131154 (1988).","journal-title":"Ann. Stat."},{"key":"3195_CR73","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017)."},{"key":"3195_CR74","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"3195_CR75","doi-asserted-by":"crossref","unstructured":"Luthra, A. et al. A.I.-assisted clinical data curation to determine genomic biomarkers of cancer metastasis. Cancer Res. 82, 1158 (2022).","DOI":"10.1158\/1538-7445.AM2022-1158"},{"key":"3195_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1148\/radiol.2021210043","volume":"301","author":"RKG Do","year":"2021","unstructured":"Do, R. K. G. et al. Patterns of metastatic disease in patients with cancer derived from natural language processing of structured CT radiology reports over a 10-year period. Radiology 301, 115\u2013122 (2021).","journal-title":"Radiology"},{"key":"3195_CR77","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1214\/08-AOAS169","volume":"2","author":"H Ishwaran","year":"2008","unstructured":"Ishwaran, H., Kogalur, U. B., Blackstone, E. H. & Lauer, M. S. Random survival forests. Ann. Appl. Stat. 2, 841\u2013860 (2008).","journal-title":"Ann. Appl. Stat."},{"key":"3195_CR78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01062-0","volume":"402","author":"J Jee","year":"2023","unstructured":"Jee, J. Machine learning-based markers for CAD. Lancet 402, 183 (2023).","journal-title":"Lancet"},{"key":"3195_CR79","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337\u2013344 (2000).","journal-title":"Biometrics"},{"key":"3195_CR80","unstructured":"Kohavi, R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In Proc. of the 14th International Joint Conference on Artificial Intelligence 1137\u20131143 (Association for Computing Machinery, 1995)."},{"key":"3195_CR81","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"3195_CR82","unstructured":"Mantha, S. CEDARS. Github https:\/\/github.com\/CEDARS-NLP\/CEDARS (2024)."},{"key":"3195_CR83","unstructured":"Mantha, S. & Singh, R. PINES. Github https:\/\/github.com\/CEDARS-NLP\/PINES (2024)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03195-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03195-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03195-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T08:25:48Z","timestamp":1726647948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03195-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3195"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03195-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J. has a patent licensed by MDSeq, Inc. J.G. is a former employee of Agilent Technologies and a current employee of NeoGenomics. J.H. and K.G. are current employees of Agilent Technologies. M.E.A. has consulted for Janssen Global Services, Bristol Myers Squibb, AstraZeneca, Roche and Biocartis and has participated in speaker\u2019s bureau activities for Biocartis, Invivoscribe, Physicians\u02bc Education Resource, PeerView Institute for Medical Education, Clinical Care Options and RMEI Medical Education. N.P. has received honoraria from Boehringer Ingelheim, Merck Sharp & Dohme, Merck, Bristol Myers Squibb, AstraZeneca, Takeda, Pfizer, Roche, Novartis, Ipsen and Bayer and received research funding from Bayer, Pfizer and Roche. S.P.S. holds equity in Canesia Health, Inc. P.R. has received research funding from GRAIL, Illumina, Novartis, Epic Sciences and ArcherDx and served as a consultant for Novartis, Foundation Medicine, AstraZeneca, Epic Sciences, Inivata, Natera and Tempus. J.S.R.-F. is a current employee of AstraZeneca; has served as a consultant for Goldman Sachs, Paige.AI and REPARE Therapeutics; and has served as an advisor for Roche, Genentech, Roche Tissue Diagnostics, Ventana, Novartis, InVicro, GRAIL, Goldman Sachs, Paige.AI and Volition RX. M.L. has received honoraria from Merck, AstraZeneca, Bristol Myers Squibb, Blueprint Medicines, Janssen Pharmaceuticals, Takeda Pharmaceuticals, Lilly Oncology, LOXO Oncology, Bayer, ADC Therapeutics, Riken Genesis and Paige.AI and research funding from LOXO Oncology, Merus and Helsinn Therapeutics. J.Z. has served as a consultant for Calyx, Sanofi, CSL Behring, Janssen, Sanofi, CSL and Parexel and received research funding from Incyte Corporation and QUercegen and honoraria from Pfizer\/Bristol Myers Squibb, Portola and Daiichi. M.F.B. has consulted for PetDx and Eli Lilly and received research funding from GRAIL. B.T.L. has received research funding from Amgen, Genentech, AstraZeneca, Daiichi Sankyo, Eli Lilly, Illumina, GRAIL, Guardant Health, Hengrui Therapeutics, MORE Health and Bolt Biotherapeutics. S.M. has served as a consultant for Janssen Pharmaceuticals; is developing a licensing agreement with Superbio.ai, Inc. for NLP software featured in this paper; is the principal owner of Daboia Consulting, LLC; and has a US patent application for PINES. J.J., B.T.L. and S.M. have applied for a US patent related to the research in this paper. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}